teprotumumab Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$11380.9000 - $14900.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

r1507 | r 1507 | r-1507 | r-1507 monoclonal antibody | rg1507 | rg 1507 | rg-1507 | rg-1507 monoclonal antibody | ro-4858696 | ro-4858696000 | teprotumumab

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue